Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Chernausek, P. Backeljauw, J. Frane, J. Kuntze, L. Underwood (2007)
Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.The Journal of clinical endocrinology and metabolism, 92 3
J Clin Endrocrinol Metab, 86
S. Kemp (2012)
Insulin-Like Growth Factor-I Deficiency in Children with Growth Hormone InsensitivityBioDrugs, 23
L. Midyett, A. Rogol, A. Rogol, Quentin Meter, J. Frane, G. Bright (2010)
Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.The Journal of clinical endocrinology and metabolism, 95 2
P. Backeljauw, L. Underwood (2001)
Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.The Journal of clinical endocrinology and metabolism, 86 4
M. Scheinowitz, M. Feinberg, Z. Laron, (2009)
IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 19 3
D. Fintini, C. Brufani, M. Cappa (2009)
Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiencyTherapeutics and Clinical Risk Management, 5
Hormres Paediatr, 83
P. Bang, M. Polak, J. Woelfle, A. Houchard (2015)
Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex® Growth Forum Database ExperienceHormone Research in Paediatrics, 83
R. Rosenfeld (2007)
IGF-I therapy in growth disorders.European journal of endocrinology, 157 Suppl 1
J. Puche, I. Castilla-Cortázar (2012)
Human conditions of insulin-like growth factor-I (IGF-I) deficiencyJournal of Translational Medicine, 10
Z. Ungvari, A. Csiszar (2012)
The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances.The journals of gerontology. Series A, Biological sciences and medical sciences, 67 6
J. Guevara-Aguirre, A. Rosenbloom, O. Vasconez, V. Martinez, S. Gargosky, L. Allen, Ron Rosenfeld (1997)
Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.The Journal of clinical endocrinology and metabolism, 82 2
Jay Cohen, S. Blethen, J. Kuntze, S. Smith, K. Lomax, P. Mathew (2014)
Managing the Child with Severe Primary Insulin-Like Growth Factor-1 Deficiency (IGFD): IGFD Diagnosis and ManagementDrugs in R&D, 14
Z. Laron, (2004)
Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003.The Journal of clinical endocrinology and metabolism, 89 3
M. Feinberg, M. Scheinowitz, Z. Laron, (2000)
Echocardiographic dimensions and function in adults with primary growth hormone resistance (Laron syndrome).The American journal of cardiology, 85 2
AbstractBackground:Laron syndrome (LS), which can be defined as primary growth hormone resistance or insensitivity, is a rare genetic disease inherited by an autosomal recessive trait. Although it is undistinguishable from growth hormone deficiency, LS has high levels of growth hormone, but insulin-like growth factor (IGF-1) cannot be synthesized. Mecasermin treatment is the only option for the patients who suffer from LS. This study aims to research cardiac findings of children with LS, who receive treatment with mecasermin.Methods:The study enrolled five children four males and one female, 4 M/1 F with LS, two of whom were siblings with a mean age of 6.3±2.1 years, a body weight of 13.36±4.74 kg, a height of 88±8.7 cm, and a body mass index (BMI) of 16.47±3.35. Their demographic data were obtained from their family and files. The children received mecasermin via subcutaneous injection at 0.04–0.12 μg/kg doses twice per day. The duration of mecasermin treatment was 8–53 months. All of them were examined clinically by electrocardiogram and echocardiogram.Results:Their cardiac examinations were normal, except for one case, who had systolic murmur at cardiac auscultation. Arrhythmia was not observed on their electrocardiograms. The echocardiograms did not show a significant congenital cardiac anomaly. Their cardiac measure and functions were within normal ranges. The echocardiogram of the child with the murmur showed mitral and tricuspid insufficiency. The Doppler images showed pulmonary hypertension findings. These findings were proven by angiography. The vasoreactivity test results of that patient were negative. No reason could be found for the observed pulmonary hypertension. We diagnosed this finding as a primary pulmonary hypertension and Bosentan therapy was started.Conclusions:In this study, we showed that cardiac findings were consistent with previous studies. To the best of our knowledge, the observed pulmonary hypertension in children with LS, who received treatment with or without mecasermin, is reported for first time in the literature.
Journal of Pediatric Endocrinology and Metabolism – de Gruyter
Published: Jun 27, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.